Home > D. Systemic pathology > Toxics and drugs > alemtuzumab
alemtuzumab
Wednesday 2 July 2008
Alemtuzumab (MabCampath®) is a humanized rat monoclonal antibody that targets the CD52 antigen. It has been approved for the treatment of patients with resistant chronic lymphocytic leukaemia (CLL).
